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ABSTRACT
The antitumor agent 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (1) is a potent inhibitor of
GSTP1-1, a glutathione S-transferase capable of inhibiting apoptosis by binding to JNK1 and TRAF2. We
recently demonstrated that, unlike its parent compound, the benzoyl ester of 1 (compound 3) exhibits
negligible reactivity towards GSH, and has a different mode of interaction with GSTP1-1. Unfortunately, 3
is susceptible to rapid metabolic hydrolysis. In an effort to improve the metabolic stability of 3, its ester
group has been replaced by an amide, leading to N-(6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexyl)ben-
zamide (4). Unlike 3, compound 4 was stable to human liver microsomal carboxylesterases, but retained
the ability to disrupt the interaction between GSTP1-1 and TRAF2 regardless of GSH levels. Moreover, 4
exhibited both a higher stability in the presence of GSH and a greater cytotoxicity towards cultured A375
melanoma cells, in comparison with 1 and its analog 2. These findings suggest that 4 deserves further
preclinical testing.
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Introduction
We previously synthesised the nitrobenzoxadiazole (NBD) derivative 6-
((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX, 1),
which proved to be a potent inhibitor of the human glutathione S-
transferase (GST; EC 2.5.1.18) isoform P1-1 (GSTP1-1)1. Members of the
GST family are known to catalyse conjugation of electrophilic mole-
cules, including some anticancer drugs, with the tripeptide glutathione
(GSH). This gives rise to inactive GSH conjugates which are rapidly
extruded from the cell by efflux pumps belonging to the superfamily
of ATP-binding cassette (ABC) transporters2,3. In addition, the isoform
GSTP1-1 is overexpressed in several human tumours, and inhibits
apoptosis by sequestering both the mitogen-activated protein kinase
c-Jun N-terminal kinase (JNK), and the scaffold protein TNFa-receptor-
associated-factor 2 (TRAF2)4. Since most of the currently used anti-
cancer drugs induce cancer cell death by triggering apoptosis, restor-
ation of apoptotic signalling pathways by targeting GSTP1-1 may
represent an attractive strategy for therapeutic intervention5.
We have shown that compound 1 efficiently binds to GSTP1-1
and prevents formation of hetero-complexes involving JNK and
TRAF2, thus avoiding inhibition of the apoptotic cascade mediated
by these proteins6–9. Indeed, treatment with compound 1 exhibits
remarkable pro-apoptotic activity towards cultured tumour cells,
as well as therapeutic activity in human tumour xenograft mod-
els10. In order to increase the water solubility of 1, two oxygen
atoms have been inserted in its alkyl side chain, leading to 2-(2-
(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)ethoxy)ethoxy)ethanol
(MC3181; compound 2). In vivo trials, demonstrated that thera-
peutic doses of 2 can be safely and effectively administered by
both oral and intravenous routes to mice bearing human melan-
oma xenografts11,12. However, compared to 1, compound 2 is
characterised by a greater spontaneous reactivity towards nucleo-
philes, including GSH (Di Paolo, unpublished data), a characteristic
that could accelerate its cellular efflux by the export pumps of the
multidrug-resistance protein (MRP) family13 and compromise its
therapeutic effectiveness. On the other hand, GSH transporters are
also present at the blood–brain barrier (BBB)14 and GSH deriva-
tives are efficiently exploited for drug delivery to the central ner-
vous system through recognition by GSH transporters on the
luminal side of BBB15. Moreover, some GSH analogs have been
shown to have potent neuroprotective effects16. Thus, the thera-
peutic potential of the high reactivity of some NBD derivatives
towards GSH is not fully understood at the moment.
On the basis of the hypothesis that lowering the reactivity of 1
and 2 towards nucleophilic aromatic substitution would prolong
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their lifetime in the body, and enhance their delivery to the target
protein (i.e. GSTP1-1), we are currently focussing our efforts on
developing new NBD derivatives endowed with a stability towards
nucleophilic attack by GSH higher than that of 1 and 2.
In this context, we recently reported the preparation and char-
acterisation of 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexyl
benzoate (MC2753; compound 3) that is the benzoic ester deriva-
tive of 117. Introduction of a bulky benzoyl moiety in the side
chain of the NBD scaffold of 1 has led to both a remarkable
decrease in reactivity towards GSH, and a change of the mode of
interaction with the target protein GSTP1-1. In particular, unlike 1,
compound 3 did not require GSH to trigger dissociation of the
TRAF2-GSTP1-1 complex. Moreover, the r-complex formed by
reaction of 3 with GSH in the active site of GSTP1-1 was found to
be much more stable than that of 1. This latter feature implies a
very slow enzymatic conversion of compound 3 into glutathionyl-
NBD (GS-NBD), and thus, conceivably, a more prolonged disrup-
tion of the catalytic and non-catalytic functions of the target pro-
tein. Despite its interesting features, compound 3 is not suitable
as drug candidate because of its high susceptibility to metabolism
by carboxylesterases (CES; see “Results”), a class of ubiquitously-
expressed enzymes that catalyse the hydrolysis of ester, thioester,
amide, and carbamate linkages in a wide variety of endo- and
xenobiotics18.
In an attempt to improve the hydrolytic stability of compound
3, its ester group was replaced with an amide function, leading to
N-(6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexyl)benzamide
(MC4351; compound 4). Here we report the synthesis and initial
characterisation of this novel compound, with particular attention
to its spontaneous reactivity towards GSH, interaction with GSTP1-
1, stability to human liver microsomal CES, and cytotoxic activity
towards cultured human melanoma cells.
Materials and methods
Chemicals
Unless otherwise specified, all chemicals used throughout this
work were purchased from Sigma-Aldrich Srl (Milan, Italy). GS-NDB
was synthesised as previously described1.
Chemistry
1H-NMR spectra were recorded at 400MHz on a Bruker AC 400
spectrometer (Bruker, Billerica, MA); reporting chemical shifts in d
(ppm) units relative to the internal reference tetramethylsilane
(Me4Si). All compounds were routinely checked by TLC and
1H-
NMR. TLC was performed on aluminum-backed silica gel plates
(Merck DC, Alufolien Kieselgel 60 F254, Kenilworth, NJ) with spots
visualised by UV light. Yields of all reactions refer to the purified
products. All chemicals were of the highest purity. Mass spectra
were recorded on an API-TOF Mariner by Perspective Biosystem;
samples were injected by an Harvard pump using a flow rate of
5–10 mL/min, infused in the Electrospray system. Elemental analy-
ses were performed by a PE 2400 (Perkin-Elmer, Waltham, MA)
analyser and have been used to determine purity of the described
compounds, which is >95%. Analytical results are within ±0.40%
of the theoretical values.
Preparation of N-(6-mercaptohexyl)benzamide (6)
To a solution of commercial 6-amino-1-hexanethiol hydrochloride 5
(1 eq, 0.589mmol, 100.0mg) and N,N-diisopropylethylamine (2.5 eq,
1.47mmol, 0.256mL) in dry DCM (1.5mL) was added dropwise at
0 C under nitrogen atmosphere a solution of benzoyl chloride
(1 eq, 0.589mmol, 0.068ml) in dry DCM (2mL). After stirring at
room temperature under nitrogen atmosphere for 3.5 h, the reac-
tion was stopped and the solvent evaporated. The residue was sus-
pended in water and the product extracted with ethyl acetate
(4 10mL). The organic phase was then washed in sequence with
potassium hydrogen sulphate 0.1 N (2 3mL), sodium hydrogen
carbonate saturated solution (2 3mL) and brine (1 2mL), dried
over sodium sulphate, filtered and evaporated under reduced pres-
sure. Finally, the crude product was purified by silica gel column
chromatography eluting with a mixture ethyl acetate/petroleum
ether 1:3 to give 6 as a colourless and viscous oil. Yield: 63.2%.
1H-NMR (400MHz, CDCl3) d ppm: 1.27–1.30 (t, 1H, SH), 1.32–1.44
(m, 4H, CONH(CH2)2CH2CH2(CH2)2SH), 1.53–1.60 (m, 4H, CONHCH2
CH2(CH2)2CH2CH2SH), 2.43–2.49 (m, 2H, CONH(CH2)5CH2SH),
3.37–3.42 (m, 2H, CONHCH2(CH2)5SH), 6.03 (br m, 1H, CONH),
7.36–7.45 (m, 3H, CH benzene ring), 7.67–7.71 (m, 2H, CH benzene
ring). MS (ESI), m/z: 238 [MþH]þ.
Synthesis of N-(6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-
yl)thio)hexyl)benzamide (4)
Pyridine (3.5 eq, 1.267mmol, 0.073mL) and N-(6-mercaptohexyl)ben-
zamide 6 (1 eq, 0.362mmol, 86.0mg) were added to a solution of
commercially available 4-chloro-7-nitrobenzofurazane (1 eq,
0.362mmol, 72.3mg) in 3ml of a mixture ethanol:water (1:1). After
stirring for 7 h at room temperature under nitrogen atmosphere, the
ethanol was partially evaporated under vacuum. The resulting sus-
pension was filtered and washed with water providing a crude prod-
uct that was purified by silica gel column chromatography eluting
with a mixture ethyl acetate/petroleum ether 45:55 and finally tritu-
rated with diethyl ether to yield 4 as a pure yellow powder. Yield:
43%. 1H-NMR (400MHz, CDCl3) d ppm: 1.41–1.45 (m, 2H,
CONH(CH2)2CH2(CH2)3S), 1.52–1.64 (m, 4H, CONHCH2CH2CH2CH2
(CH2)2S), 1.77–1.84 (m, 2H, CONH(CH2)4CH2CH2S), 3.18–3.22 (t, 2H,
CONH(CH2)5CH2S), 3.39–3.44 (m, 2H, CONHCH2(CH2)5S), 6.06 (br m,
1H, CONH), 7.06–7.08 (d, 1H, CH benzoxadiazole ring), 7.36–7.38 (m,
2H, CH benzene ring), 7.41–7.43 (m, 1H, CH benzene ring), 7.67–7.69
(d, 2H, CH benzene ring), 8.32–8.34 (d, 1H, CH benzoxadiazole rings).
MS (ESI), m/z: 401 [MþH]þ. Anal. (C19H20N4O4S) Calcd. (%): C, 56.99;
H, 5.03; N, 13.99; S, 8.01. Found (%) C, 57.15; H, 5.05; N, 13.88;
S, 7.96.
Evaluation of solubility and extinction coefficient (e) of
compound 4
The compound was first dissolved in 100% DMSO and then sub-
jected to scalar dilution in buffer A (0.1 M potassium phosphate, pH
7.4, containing 0.1mM EDTA and 0.1% (v/v) Triton X-100). The max-
imum solubility of these solutions was evaluated by recording the
absorbance maxima (430nm) and using a molar extinction coeffi-
cient calculated at the same wavelength, using diluted standard sol-
utions prepared in buffer A (concentration range: 4–40 mM). The
extinction coefficient was obtained by linear regression analysis of a
plot of the maximum absorbance vs. compound concentration.
Expression and purification of GSTP1-1 and TRAF2
Human GSTP1-1 expression was performed using the E. coli strain
Top 10. Single colonies of freshly plated bacteria were used to
inoculate 5-mL overnight cultures. These cultures were diluted
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into LB medium containing 100 mg/mL ampicillin and 50mg/mL
streptomycin, grown at 37 C to an A600 value of 0.5 and induced
by the addition of 0.5mM isopropyl-b-D-thiogalactopyranoside
(IPTG). Cell were grown at 37 C for 18 h, harvested by centrifuga-
tion for 15min at 7000g and resuspended in 10mM potassium
phosphate buffer, pH 7.0, containing 1mM EDTA and 10mM DTT.
Human TRAF2 was expressed in E. coli BL21 (DE3) cells, trans-
formed with the His-tagged TRAF2 C-terminal domain construct.
These cells were grown in LB medium containing 30 mg/mL kana-
mycin sulphate. Cells were grown at 37 C until the A600 value was
0.8, then the expression of TRAF2 was induced by the addition of
1mM IPTG. Thereafter, cells were grown for 18 h at 30 C.
Afterwards, cells were harvested by centrifugation and resus-
pended in 20mM Tris–HCl, pH 8.0, containing 150mM NaCl,
20mM imidazole, 10% glycerol, 1mM DTT and an EDTA-free
inhibitor of proteases. GSTP1-1 and TRAF2 cell suspensions were
sonicated and clarified by centrifugation at 20,000g for 15min,
at 4 C and the resulting supernatant was further centrifuged at
100,000g for 50min at 4 C.
GSTP1-1 was purified by affinity chromatography on a resin
with immobilised GSH19. TRAF2 was purified on a Ni-
NTA column9.
The TRAF2 and GSTP1-1 purity was analysed by SDS-PAGE. The
protein concentration was determined by measuring the absorb-
ance at 280 nm and using an extinction coefficient of 17,780 and
25,460 M1 cm1 for TRAF2 and GSTP1-1 monomers, respectively.
Proteins were stored at –80 C.
Kinetic analysis
The enzymatic activity of GSTP1-1 (20 nM subunits) was spectro-
photometrically assayed at 340 nm (e¼ 9,600 M1 cm1) and at
25 C, by measuring the rate of 1-cloro-2,4-dinitrobenzene (CDNB)
conjugation with GSH as a function of time20. The assay mixture
contained 1mM GSH and 1mM CDNB in 1mL of buffer B (0.1 M
potassium phosphate buffer, pH 6.5 containing 0.1mM EDTA). The
inhibitory potency of the compounds was determined by record-
ing the activity of GSTP1-1 in the presence of increasing concen-
trations of the selected NBD derivative (0.01–20 mM).
Evaluation of the stability of compounds 1–4 in the presence
of GSH
Each test compound (10 mM) was incubated in a mixture (final vol-
ume, 0.2mL) containing 0.1 M potassium phosphate (pH 7.4) and
1mM GSH; control incubations were performed in the absence of
GSH (buffer-only incubations). The reactions were conducted at
37 C for different time intervals, and terminated by adding 10 mL
of 20% (p/v) perchloric acid and 100 mL of ice-cold acetonitrile.
Time 0 samples were prepared by adding all the components of
the mixture to ice-cold test tubes containing 10 mL of 20% (p/v)
perchloric acid, and 100 mL of acetonitrile. Samples were then cen-
trifuged at 20,000g for 10min (4 C) to separate the precipitates
of potassium perchlorate, and aliquots of the supernatants were
analysed for the disappearance of the test compound by HPLC
with visible absorbance detection, as described below.
Evaluation of the stability of compounds 3 and 4 in human
liver microsomes
Compound 3 or 4 (10 mM) was incubated in a medium (final vol-
ume, 0.2mL) containing 0.1 M potassium phosphate (pH 7.4) and
0.05mg of protein/mL of pooled, mixed-gender human liver
microsomes (Xenotech, LLC, Lenexa, KS, USA; HLMs); control incu-
bations were performed in the absence of HLMs. The reactions
were conducted at 37 C for different time intervals and termi-
nated by adding 0.1mL of ice-cold acetonitrile. Time 0 samples
were prepared by adding all the components of the mixture to
ice-cold test tubes containing 0.1mL of acetonitrile. Samples were
then centrifuged at 20,000g for 10min (4 C), and aliquots of the
supernatants were analysed for the disappearance of the test
compound by HPLC with visible absorbance detection, as
described below.
The role of human liver microsomal CES in hydrolysis of com-
pound 3 was investigated by incubating the test compound
(10 mM) at 37 C for 0 and 10min in 0.2mL of 0.1 M potassium
phosphate buffer (pH 7.4) containing 0.05mg of protein/mL of
pooled, mixed-gender HLMs (Xenotech LLC) and the nonselective
CES inhibitor benzil (50 mM)21; the incubation protocol and sample
preparation for HPLC analysis were the same as described above.
Control incubations were carried out in the absence of benzil.
HPLC analysis
Analysis were conducted using a Hewlett-Packard series 1100
HPLC system (Agilent Technologies, formerly Hewlett-Packard,
Palo Alto, USA) equipped with a degasser, a quaternary pump, an
autosampler, a column oven, a variable wavelength UV–visible
detector, and a diode-array detector; data were collected and inte-
grated using the Agilent ChemStation software. Chromatographic
conditions were as follows: column, Agilent Zorbax Eclipse XDB-
C18 (3.0 150mM, 5 mm; Agilent Technologies); mobile phase,
10mM ammonium bicarbonate, pH 6.8/acetonitrile (90:10 v/v;
solvent A) and acetonitrile (solvent B); elution programme, iso-
cratic elution with 100% solvent A for 2min, linear gradient from
0 to 70% solvent B in 8min, followed by an isocratic elution with
70% solvent B until the end of the chromatographic run; post-run
time, 7min; flow rate, 0.4mL/min.; injection volume, 30 mL; col-
umn temperature, 28 C; detection, absorbance at 433 nm. Under
the above conditions, retention times of compounds 1, 2, 3, 4
and GS-NBD were 13.2, 11.4, 20.9, 14.4, and 5.9min, respectively.
ELISA for protein–protein interaction analysis
The formation of the TRAF2-GSTP1-1 complex was studied as
previously described9. Briefly, 200 mL of His-tagged TRAF2 C-ter-
minal domain (0.005 mM in 20mM Tris–HCl, pH 7.6, containing
150mM NaCl and 10% glycerol) were added to each well of a
96-well His-Sorb plate (Qiagen, Hilden, Germany) and incubated
overnight, at 4 C, on a rocking platform. Afterwards, wells were
washed with PBS and incubated for 30min with GSTP1-1 (con-
centration range from 0.1 to 2 mM) in 10mM potassium phos-
phate buffer, pH 7.0, containing 0.1mM EDTA. Incubation with
GSTP1-1 was also performed in the presence of 1 (20 mM), 3
(20 mM) or 4 (20 mM), both in the absence and presence of GSH
(1mM). At the end of incubation, the wells were washed with
PBS and then filled with 200 mL of a mouse anti-GSTP1-1 anti-
body (Cell Signalling, Beverly, MA, USA; 1:1000 in TBS containing
0.1% Tween and 5% non-fat dry milk) for 2 h at room tempera-
ture. Subsequently, wells were washed with PBS and incubated
with an antimouse IgG antibody (Cell Signalling; 1:1000 in TBS
containing 0.1% Tween and 5% non-fat dry milk) for 45min at
room temperature. The immunocomplexes were detected by
the addiction of 200 mL/well of the 1-Step-Turbo TMB substrate
solution (Pierce, Rockford, IL, USA). The reaction was stopped
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after 10min by the addition of 50 mL of 2M H2SO4, and the
absorbance was measured at 450 nm. Data were analysed by fit-
ting to Equation (1) where  is the percentage of the saturated
binding sites of TRAF2; [P]t and [L]t are the total concentrations
of monomeric GSTP1-1 and TRAF2, respectively22.
 ¼ 100 P
½ t þ L½ t þ Kd
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P½ t þ L½ t þ Kd
 2  4 P½ t L½ t
q
2 L½ t
(1)
Cytotoxicity experiments
The human melanoma A375 cell line was obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA). Cells
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM),
supplemented with 10% foetal bovine serum FBS (v/v), 2mM L-
glutamine, 100U/mL penicillin and 100mg/mL streptomycin, at
37 C in a 5% CO2 humidified atmosphere. For cell viability stud-
ies, A375 (2.0 104 cells/cm2) were seeded in 96-well plates and,
after 24 h at 37 C, were exposed to different concentrations of
NBD-derivatives (0.05–25.0 mM) for 48 h. After incubation, cell sur-
vival was evaluated by the sulforodamine B (SRB) assay23, as previ-
ously described6.
Molecular docking
Molecular docking simulations were used to asses binding affin-
ities and poses using Autodock Vina24, a recent and efficient
implementation of docking software from Molecular Graphics
Laboratory (MGL) of The Scripps Research Institute. Receptors
were prepared starting from crystal structures of the apo-GSTP1-1,
PDB code 5DCG25 and the GSH-NBDHEX complexed structure,
PDB code 3GUS26. Water and cosolutes were removed from the
structure which was further corrected for multiple occupancies
using UCSF Chimera27.
The structures of 3 and 4 were initially built using the
Chimaera programme and then processed in AutoDockTools
assigning partial charges using the Gasteiger method. All suit-
able ligand dihedrals were allowed to rotate. The docking grid
was centred on the GST active site and large volume
(22.75 22.75 28.25 Å) was used to allow extensive conform-
ational sampling. The number of binding modes for each run
was set to 15 and exhaustiveness parameter to 25. To enhance
sampling five runs were executed independently, each starting
from a different random seed, and the results were merged. The
final 75 structures were ranked according to the most favour-
able docking energy and clustered according to relative root-
mean-square-deviations. Docked structures were analysed with
AutoDockTools and Pymol which was also used to prepare
Figures 1 and 2.
Data analysis
Unless specified otherwise, experiments were repeated at least
three times, and results are presented as mean± SD. The Student’s
t test for unpaired data was used for comparison of the mean val-
ues between two groups. Differences were considered statistically
significant when P< 0.05.
Metabolic stability of each test compound, expressed as per-
centage of compound remaining (mean± SD; n¼ 3), was calcu-
lated by comparing the corresponding chromatographic peak area
at each time point relative to that at time 0min. Disappearance
half-live values of the studied NBD derivatives were calculated by
non-linear regression analysis of the data, using a one-phase
exponential decay model28, provided by GraphPad Prism
(GraphPad Software, San Diego, CA, USA).
Results
Chemistry
The benzamide derivative 4 has been prepared starting from the
commercial 6-amino-1-hexanthiol 5, that has been first acylated
with benzoyl chloride to provide the intermediate N-(6-mercapto-
hexyl)benzamide 6, that has been finally converted into the desired
N-(6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexyl)benzamide 4
through the nucleophilic displacement with the commercially
available 4-chloro-7-nitrobenzofurazane (Scheme 1).
Figure 1. Protein-ligand docking analysis: best binding poses for 3 and 4. Both
compounds show a similar arrangement in their lowest energy poses, with a
shifted NBD moiety and the benzoyl terminal making extensive contact with Phe
8. Crystal position for 1 is shown in red lines for reference, GST is shown in surface
representation, with contributions coming from Phe 8 in orange (also shown in
sticks) and those from Helix 2 in blue. GSH is also shown in sticks representation.
Figure 2. Protein-ligand docking analysis: alternative binding mode for 3 and 4.
Both 3 (brick) and 4 (purple) exhibit a higher energy alternative binding pose
which stretches toward the other monomer of GST. Compound 1 crystal position
is shown in red sticks for reference and GSH is indicated in lines.
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Comparison of chemical and physical properties of
compounds 1–4
The molecular weights, extinction coefficients, and the aqueous
solubility profiles of 4, of its parent compound 1, and its analogs
2 and 3 are reported in Table 1. The structures and UV–vis spectra
of 3 and 4 are also shown in Figure 3. Compound 4 showed an
extinction coefficient at 430 nm of 14.9 (mM1 cm1) and a solu-
bility limit of approximately 0.08mM, a value slightly higher than
that of 3 (0.05mM)17.
Compound 4 exhibits a lower reactivity towards GSH than
compounds 1 and 2
The spontaneous reactivity of 4 towards GSH was compared with
that of compounds 1–3; in these HPLC-based trials, each NBD
derivative (10mM) was incubated at 37 C for different time inter-
vals in a phosphate buffer (pH 7.4) containing a physiological
intracellular concentration of GSH (1mM). Both compound 1 and
2 reacted quickly with GSH, with estimated half-lives of 7 and
1min, respectively (Figure 4); loss of both compounds from the
incubation mixture correlated with the appearance of a new
prominent chromatographic peak having a retention time and an
absorbance spectrum identical to that of authentic GS-NBD (not
shown). Compound 4 was remarkably less reactive towards GSH
than 1 and 2, with an estimated half-life (30min) closer to that
of compound 3 (100min). Thus, the isosteric replacement of the
ester moiety of 3 with an amide function is accompanied by only
a limited increase of spontaneous reactivity towards GSH under
physiological conditions of pH, temperature and concentration of
the tripeptide3.
Compound 4 displays GSTP1-1 catalytic activity inhibition
properties superior to those of compounds 2 and 3
The chemical and physical properties of compounds 3 and 4 have
been evaluated in a buffer containing 0.1% (v/v) Triton X-100.
However, we previously found that the presence of a nonionic
surfactant decreased the affinity of GSTP1-1 for both compounds
1 and 317. Therefore, GSTP1-1 activity inhibition experiments were
performed by dissolving both compound 3 and 4 in a detergent-
free buffer. Under these conditions, compound 3 inhibited GSTP1-
1 conjugation activity no more than 50% (Figure 5), as previously
observed17. In contrast, like compound 1 (Ki
app¼0.8 ± 0.1mM)11,
compound 4 completely inhibited GSTP1-1 enzyme activity
(Ki
app¼0.7 ± 0.1 mM; Figure 5). Therefore, despite its structural simi-
larity with 3, compound 4 displays inhibitory properties towards
GSTP1-1 catalytic activity comparable to those of its parent com-
pound, i.e. compound 1. Notably, the GSTP1-1 inhibition potency
of compounds 1 and 4 was 3-fold higher than that of the more
water-soluble analog 2 (Ki
app¼2.6 ± 0.3mM; Table 2)11.
Compound 4 disrupts the interaction between GSTP1-1 and
TRAF2 both in the presence and in the absence of GSH
We have previously shown that compound 1 is capable of reduc-
ing the affinity of GSTP1-1 for TRAF2 only in the presence of GSH.
By contrast, compound 3 was found to be very efficient in weak-
ening the interaction between TRAF2 and GSTP1-1 even in the
absence of the tripeptide17. Noteworthy, compound 4 showed a
behaviour comparable to that of 3, i.e. inhibited TRAF2-GST-P1-1
complex formation both in the absence and in the presence of
GSH (Figure 6).
Compound 4 displays a high stability in the presence of human
liver microsomes
As shown in panel A of Figure 7, the ester linkage-containing NBD
derivative compound 3 was stable when incubated at 37 C in
phosphate buffer (pH 7.4) only, but time-dependently disappeared
when HLMs where included in the mixture, giving rise to com-
pound 1 (not shown). Metabolic depletion of 3 was remarkably
inhibited by 50 mM benzil21, a finding indicating the involvement
of one or more human liver microsomal CES in the hydrolytic
reaction (Figure 7, panel C). In contrast, compound 4 (i.e. the
amide analog of 3) was quite stable both in phosphate buffer
only and in the presence of HLMs (Figure 7, panel B).
Compound 4 exhibits remarkable antitumor activity towards
cultured human melanoma cells
A last set of in vitro experiments compared the cytotoxicity of
compound 4 with that of compounds 1 and 2 in A375 human
melanoma cells, using an SRB assay; results of these trials are sum-
marised in Figure 8 and Table 2. Interestingly, the IC50 value of 4
(0.24 ± 0.01 mM) was 3- and 2-fold lower than that of 2
(0.77 ± 0.03 mM) and 1 (0.37 ± 0.02 mM), respectively.
Scheme 1. Preparation of compound 4. (a) Benzoyl chloride, N,N-diisopropylethylamine, dry DCM, N2, 0 C to rt; (b) 4-chloro-7-nitrobenzofurazane, pyridine, ethanol/
water 1:1, N2, rt.
Table 1. Molecular weights, extinction coefficients and solubility limits.
Compound
Molecular
weight (Da)
Extinction
coefficient (e)
(mM–1 cm–1)
Solubility
(mM)
1 (NBDHEX) 297.3 15.0a 0.1e
2 (MC3181) 329.3 16.4b 5.0e
3 (MC2753) 401.4 12.5c 0.050f
4 (MC4351) 400.5 14.9d 0.080f
ae at 433 nm.
be at 425 nm reported by De Luca et al.11
ce at 430 nm reported by Fulci et al.17
de at 430 nm.
e0.1 M K-Phosphate buffer, pH 7.4, reported by De Luca et al.11
f0.1 M K-Phosphate buffer, pH 7.4, containing 0.1% (v/v) Triton X-100.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 1135
Docking results
Molecular docking simulations were used to try to capture differen-
ces in binding modes that could account for different dynamical
and functional behaviour of 3 and 4. Results on the GSH loaded
enzyme show that both inhibitors bind with high affinity in an elon-
gated pose along the cleft of the H binding site of GSTP1-1. The
NBD moiety is slightly deeper in the cavity with respect to that of
the parent compound 1, and the terminal benzoyl moiety is in close
contact with the hydrophobic Phe 8 residue (Figure 1). The inter-
action energy reaches –8.4 and –8.8 kcal/mol for 3 and 4, respect-
ively. Consistently with our previous results, a different binding
mode was also found for 3 and 4, albeit at lower binding energies
(with maximum at –7.4 and –7.8 kcal/mol, respectively). In this mode
the NBD is displaced from the crystal position and the benzoyl moi-
ety is stretched toward the cavity lying behind Lys 102 of the other
monomer, towards Tyr 49 (Figure 2).
Discussion
Over the last few years, many efforts have been made to improve
the delivery of antitumor NBD derivatives through an increase of
their solubility in aqueous vehicles. These endeavours resulted in
compounds with a greater spontaneous reactivity towards nucleo-
philic attack by GSH, a characteristic that conceivably translates
into a faster in vivo conversion to rapidly excreted
GSH conjugates.
More recently we synthesised and characterised compound 3,
i.e. the benzoyl ester derivative of the prototypical antitumor NBD
derivative 1. Introduction of the bulky benzoyl moiety in the side
chain of compound 1 led to a compound endowed with different
features, including a remarkable stability towards GSH under
physiological conditions17. Unfortunately, compound 3, like several
Figure 3. Spectrophotometric analysis. Structures and UV–visible spectra of 3 and 4 (20 mM), dissolved in buffer A, pH 7.4. Both spectra were recorded at 25 C.
Figure 4. Spontaneous reactivity of compounds 1–4 towards GSH. Each NBD
derivative (10 mM) was incubated with 1mM GSH in 0.1 M potassium phosphate
(pH 7.4) at 37 C for different time intervals. The data are expressed as percent-
age of compound remaining at each time compared with time 0min, and repre-
sent the mean± SD of three independent determinations. Error bars smaller than
the symbols are not visible.
Figure 5. Inhibition of GTP1-1 conjugation activity. Inhibition of GSTP1-1 by 3
and 4 was evaluated at 25 C. The assay mixture contained 1mM GSH, and 1mM
CDNB in 1mL of buffer B (0.1 M potassium phosphate buffer, pH 6.5, containing
0.1mM EDTA). Data points represent the mean± SD from three independent
experiments. Error bars smaller than the symbols are not visible.
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other carboxyl ester linkage-containing compounds, is highly sus-
ceptible to hydrolysis catalysed by CES29 (see panels A and C of
Figure 7), a feature limiting its availability in biological systems.
However, the isosteric replacement of the carboxyl ester linkage
of 3 with an amide moiety was successful in improving the stabil-
ity to metabolic hydrolysis. Indeed, compound 4, the amide ana-
log of 3, was found to be quite stable to human liver microsomal
esterases (panel B, Figure 7). Interestingly, the adopted isosteric
replacement completely changed the pattern of inhibition of
Table 2. GSTP1-1 and cell growth inhibition data.
Compound
GSTP1-1
inhibition assay
IC50 (mM)
A375
cytotoxicity assay
IC50 (mM)
1 (NBDHEX) 0.8 ± 0.1a 0.37 ± 0.02
2 (MC3181) 2.6 ± 0.3a 0.77 ± 0.03
3 (MC2753) 0.6 ± 0.3b –
4 (MC4351) 0.7 ± 0.1 0.24 ± 0.01
aIC50 values reported by De Luca et al.
11
bIC50 value reported by Fulci et al.
17
Figure 6. Inhibition of the TRAF2-GSTP1-1 interaction. (A) His-tagged TRAF2 (0.005 mM) was immobilised on Ni-NTA-coated plates and incubated at pH 7.0 with
increasing amounts of GSTP1-1 (from 0.1 to 2 mM) in the absence (--) or in the presence of compounds 1 (-w- 20 mM), 3 (-^- 20 mM) or 4 (-- 20 mM). (B) The
same experiments were repeated also in the presence of GSH (1mM). In this case, the binding trend of 1 overlaps those obtained with 3 and 4. Data points represent
the mean± SD from three independent experiments. Error bars smaller than the symbols are not visible.
Figure 7. Assessment of metabolic stability of compounds 3 and 4 in human liver microsomes (HLMs). Compound 3 (panel A) or 4 (panel B) was incubated with
pooled, mixed-gender HLMs (0.05mg of protein/mL) in 0.1 M potassium phosphate buffer, pH 7.4 (-	-) or buffer only (-w-) at 37 C for various time intervals (n¼ 5).
The final concentration of each NBD derivative in the incubation mixture was 10 mM. To evaluate the role of CES on depletion of 3 in human liver microsomal incuba-
tions, the NBD derivative (10 mM) was incubated at 37 C with pooled, mixed-gender HLMs (0.05mg of protein/mL) in 0.1 M potassium phosphate buffer (pH 7.4) for
0 and 10min, both in the absence and in the presence of 50 mM benzil (panel C). The data are expressed as percentage of compound remaining at each time com-
pared with time 0min, and represent the mean± SD of three independent determinations. Error bars smaller than the symbols are not visible. P< 0.001 vs. control
(minus benzil) at 10min.
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GSTP1-1 catalytic activity; compound 4, like 1, was able to fully
abolish the enzymatic activity of GSTP1-1, while compound 3
inhibited enzyme activity no more than 50% (Figure 5). Molecular
docking orientations obtained for 3 within the GSTP1-1 active site
showed, among the clusters with the most favourable binding
energies, a pose in which the benzoyl ring of 3 is placed at the
interface between the protein monomers, in close proximity with
the side chain of Tyr 4917. It is possible to speculate that this
binding mode could account for the half-site inhibition of GSTP1-
1 observed in the presence of 3. However, the very similar bind-
ing pose and energy found also for 4 suggest a more complex
enzyme inhibition mechanism that cannot be inferable from the
static picture provided by docking. Nevertheless, compound 4 was
still capable of affecting formation of the TRAF2-GSTP1-1 complex
even in the absence of GSH (Figure 6). These findings suggest
that the presence of the ester oxygen atom is not a structural
requisite to interfere with the interaction between TRAF2 and
GSTP1-1. The highest affinity poses of 3 and 4 show the terminal
benzoyl moiety in close contact with the hydrophobic Phe 8 resi-
due. The steric hindrance of the benzoyl moiety in that position
can account very well for the restricted mobility of helix 2 of
GSTP1-1, which was demonstrated to be crucial for TRAF2 bind-
ing30. Similar poses are found in the high scoring results of dock-
ing on the Apo-GST structures, thus explaining the inhibition of
TRAF2-GSTP1-1 binding even in the absence of GSH. The lack of
influence of GSH on the ability of compound 4 to disrupt the
interaction between TRAF2 and GSTP1-1 is a relevant feature since
GSH levels fluctuate in healthy mammalian organs31,32, in several
human tumours3, as well as in the brain of patients affected by
neurodegenerative disorders15.
Notably, the presence of a bulky hydrophobic moiety in the
side chain of the NBD scaffold of 3 and 4 hinders nucleophilic aro-
matic substitution reactions. Indeed, like 3, compound 4 exhibited
a stability greater than 1 and 2 when incubated with GSH under
physiological conditions (Figure 4). Since ongoing in vitro drug
metabolism studies indicate that 1 undergoes inactivation by
both glucuronidation and oxidation of the side-chain hydroxyl
group (Di Paolo et al., unpublished data), replacement of the
hydroxyl group of 1 with the benzoyl amide moiety eliminates
these possible metabolic inactivation pathways. Finally, the herein
reported in vitro antitumor activity experiments suggest a
correlation between the high stability of 4 and its excellent cyto-
toxic activity towards human melanoma cells. In light of these
results, future studies will be aimed mainly at identifying a suit-
able formulation to allow the in vivo delivery of this novel antitu-
mor NBD derivative.
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